{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:31:15Z","timestamp":1792042275674,"version":"4.4.0"},"reference-count":398,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1919,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1124\/pr.118.017129","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T07:39:05Z","timestamp":1568878745000},"page":"539-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":300,"title":["Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure"],"prefix":"10.1016","volume":"71","author":[{"given":"Lauren B.","family":"Arendse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M.","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John C.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Llorens-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario R.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.118.017129_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2004.04.004","article-title":"Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance","volume":"102","author":"Abassi","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.118.017129_bib2","doi-asserted-by":"crossref","first-page":"39721","DOI":"10.1074\/jbc.M105253200","article-title":"The angiotensin II AT2 receptor is an AT1 receptor antagonist","volume":"276","author":"AbdAlla","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/35024095","article-title":"AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration","volume":"407","author":"AbdAlla","year":"2000","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s001340050413","article-title":"Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome","volume":"23","author":"Agah","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1124\/pr.118.017129_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20102123","article-title":"Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide","volume":"436","author":"Akif","year":"2011","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib6","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1021\/jm00186a020","article-title":"Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme","volume":"23","author":"Almquist","year":"1980","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-4889(91)90248-V","article-title":"The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors","volume":"1133","author":"Ambroz","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pr.118.017129_bib8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"issue":"Suppl B","key":"10.1124\/pr.118.017129_bib9","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1124\/pr.118.017129_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clpt.2005.09.011","article-title":"Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans","volume":"79","author":"Azizi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.118.017129_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000523071.55675.05","article-title":"[OP. 4A. 08] A randomized double-blind placebo controlled crossover study to compare QGC001, a brain aminopeptidase A inhibitor, with placebo in patients with grade I\/II essential hypertension (Abstract)","volume":"35","author":"Azizi","year":"2017","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.HYP.33.3.879","article-title":"Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans","volume":"33","author":"Azizi","year":"1999","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/pr.113.008136","article-title":"MAS and its related G protein-coupled receptors, Mrgprs","volume":"66","author":"Bader","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/HYPERTENSIONAHA.118.10918","article-title":"The meaning of Mas","volume":"72","author":"Bader","year":"2018","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejphar.2015.05.059","article-title":"Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage","volume":"762","author":"Bai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-013-0125-y","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase A inhibitor prodrug","volume":"53","author":"Balavoine","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.118.017129_bib17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.1997.7394","article-title":"Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation","volume":"238","author":"Barton","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.118.017129_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.iac.2016.08.011","article-title":"The angiotensin-converting-enzyme-induced angioedema","volume":"37","author":"Bas","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1124\/pr.118.017129_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/01.HYP.3.6_Pt_2.II-14","article-title":"Renin-like activity in the rat brain during the development of DOC-salt hypertension","volume":"3","author":"Basso","year":"1981","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib23","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in Circulation (2017) 135:e646 and 136:e196]","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib24","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/01.CIR.99.15.2034","article-title":"Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells","volume":"99","author":"Benzing","year":"1999","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.112.006809","article-title":"A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme","volume":"65","author":"Bernstein","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coph.2010.11.001","article-title":"Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE)","volume":"11","author":"Bernstein","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pr.118.017129_bib27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.118.017129_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","article-title":"Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors","volume":"121","author":"Bosnyak","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib30","doi-asserted-by":"crossref","first-page":"17596","DOI":"10.1074\/jbc.M000142200","article-title":"Regulation and intracellular trafficking pathways of the endothelin receptors","volume":"275","author":"Bremnes","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/protein\/14.5.337","article-title":"A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP)","volume":"14","author":"Bur","year":"2001","journal-title":"Protein Eng"},{"key":"10.1124\/pr.118.017129_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20130808","article-title":"Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension","volume":"127","author":"Burger","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition\u2014implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1124\/pr.118.017129_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI112566","article-title":"Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat","volume":"78","author":"Campbell","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.118.017129_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/pr.118.017129_bib36","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/CIRCULATIONAHA.110.981720","article-title":"Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats","volume":"123","author":"Cataliotti","year":"2011","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","article-title":"Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme","volume":"31","author":"Chappell","year":"1998","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib38","first-page":"129","article-title":"Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4. 24.15) in vascular smooth muscle cells","volume":"5","author":"Chappell","year":"1995","journal-title":"J Vasc Med Biol"},{"key":"10.1124\/pr.118.017129_bib39","first-page":"R373","article-title":"Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep","volume":"271","author":"Charles","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.118.017129_bib40","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/jm00044a016","article-title":"Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols","volume":"37","author":"Chauvel","year":"1994","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib41","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2012.07.056","article-title":"Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib42","doi-asserted-by":"crossref","first-page":"R407","DOI":"10.1152\/ajpregu.00286.2017","article-title":"CRRL269: a novel designer and renal-enhancing pGC-A peptide activator","volume":"314","author":"Chen","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pr.118.017129_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/BJ20080471","article-title":"Asp218 participates with Asp213 to bind a Ca2+ atom into the S1 subsite of aminopeptidase A: a key element for substrate specificity","volume":"416","author":"Claperon","year":"2008","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib44","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(02)00389-3","article-title":"Omapatrilat--the story of Overture and Octave","volume":"86","author":"Coats","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1124\/pr.118.017129_bib46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1172\/JCI112723","article-title":"Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion","volume":"78","author":"Cody","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.118.017129_bib47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(91)91254-X","article-title":"The AT2 angiotensin receptor subtype predominates in the 18 day gestation fetal rat brain","volume":"560","author":"Cook","year":"1991","journal-title":"Brain Res"},{"key":"10.1124\/pr.118.017129_bib49","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1021\/bi700275e","article-title":"The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380","volume":"46","author":"Corradi","year":"2007","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib50","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jmb.2006.01.048","article-title":"Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design","volume":"357","author":"Corradi","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1124\/pr.118.017129_bib51","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/bi012121x","article-title":"Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides","volume":"41","author":"Cotton","year":"2002","journal-title":"Biochemistry"},{"issue":"22","key":"10.1124\/pr.118.017129_bib398","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.1021\/acs.jmedchem.8b01309","article-title":"Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain","volume":"61","author":"Cozier","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib52","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1021\/bi00644a014","article-title":"Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids","volume":"16","author":"Cushman","year":"1977","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1124\/pr.118.017129_bib55","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nature05475","article-title":"Essential role for collectrin in renal amino acid transport","volume":"444","author":"Danilczyk","year":"2006","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pharmthera.2006.12.001","article-title":"ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?","volume":"113","author":"Danser","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.118.017129_bib57","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-199816121-00005","article-title":"Angiotensinogen (M235T) and angiotensin-converting enzyme (I\/D) polymorphisms in association with plasma renin and prorenin levels","volume":"16","author":"Danser","year":"1998","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.96.1.220","article-title":"Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding","volume":"96","author":"Danser","year":"1997","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib59","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjhyper.2005.06.022","article-title":"Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats","volume":"18","author":"Daull","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.118.017129_bib60","first-page":"830","article-title":"Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats","volume":"231","author":"Daull","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1124\/pr.118.017129_bib61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/01480540600566717","article-title":"The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats","volume":"29","author":"Daull","year":"2006","journal-title":"Drug Chem Toxicol"},{"key":"10.1124\/pr.118.017129_bib62","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1021\/jm9903040","article-title":"Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme","volume":"42","author":"David","year":"1999","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1976.56.1.1","article-title":"Mechanisms regulating renin release","volume":"56","author":"Davis","year":"1976","journal-title":"Physiol Rev"},{"key":"10.1124\/pr.118.017129_bib64","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.RES.83.10.1047","article-title":"The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes","volume":"83","author":"Davisson","year":"1998","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib65","first-page":"S3","article-title":"Functional-morphological studies on in vitro cardionatrin release","volume":"4","author":"de Bold","year":"1986","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/pr.118.017129_bib66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International Union of Pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib67","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.HYP.29.6.1240","article-title":"Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I","volume":"29","author":"de Lannoy","year":"1997","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib68","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/01.HYP.31.4.912","article-title":"N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE","volume":"31","author":"Deddish","year":"1998","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0014-5793(95)00249-9","article-title":"Processing of proendothelin-1 by human furin convertase","volume":"362","author":"Denault","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1124\/pr.118.017129_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.amjcard.2004.03.074","article-title":"Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure","volume":"94","author":"Dickstein","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1124\/pr.118.017129_bib71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/ci9005047","article-title":"A computational approach to the study of the binding mode of dual ACE\/NEP inhibitors","volume":"50","author":"Dimitropoulos","year":"2010","journal-title":"J Chem Inf Model"},{"key":"10.1124\/pr.118.017129_bib72","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.96.8.4330","article-title":"RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites","volume":"96","author":"Dive","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib73","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/CS20130403","article-title":"Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors","volume":"126","author":"Douglas","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","article-title":"Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor","volume":"62","author":"Edwards","year":"1988","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib76","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1021\/bi9602425","article-title":"Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence","volume":"35","author":"Ehlers","year":"1996","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib77","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cardfail.2009.01.014","article-title":"Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes","volume":"15","author":"Epelman","year":"2009","journal-title":"J Card Fail"},{"key":"10.1124\/pr.118.017129_bib78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","article-title":"Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system","volume":"52","author":"Epelman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1096\/fasebj.3.2.2521610","article-title":"Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones","volume":"3","author":"Erd\u00f6s","year":"1989","journal-title":"FASEB J"},{"key":"10.1124\/pr.118.017129_bib80","article-title":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human","volume":"9","author":"Fagyas","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pr.118.017129_bib81","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.jacc.2016.09.946","article-title":"Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction","volume":"68","author":"Fattah","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00004872-199507000-00012","article-title":"Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension","volume":"13","author":"Favrat","year":"1995","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib83","first-page":"e766","article-title":"Efficacy and safety of a novel antihypertensive pharmacotherapy approach in a high-risk diverse population (Abstract)","volume":"138","author":"Ferdinand","year":"2018","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.phrs.2017.05.020","article-title":"Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease","volume":"125","author":"Ferrario","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1124\/pr.118.017129_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.regpep.2006.12.031","article-title":"Angiotensin-(3-7) pressor effect at the rostral ventrolateral medulla","volume":"141","author":"Ferreira","year":"2007","journal-title":"Regul Pept"},{"key":"10.1124\/pr.118.017129_bib86","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib87","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acs.jmedchem.7b01478","article-title":"The design and development of a potent and selective novel diprolyl derivative that binds to the N-domain of angiotensin-I converting enzyme","volume":"61","author":"Fienberg","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib88","doi-asserted-by":"crossref","first-page":"F210","DOI":"10.1152\/ajprenal.00389.2017","article-title":"Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade","volume":"314","author":"Fitzgibbon","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pr.118.017129_bib89","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1113\/jphysiol.2010.203075","article-title":"Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor","volume":"589","author":"Flores-Mu\u00f1oz","year":"2011","journal-title":"J Physiol"},{"key":"10.1124\/pr.118.017129_bib90","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/HYPERTENSIONAHA.111.177485","article-title":"Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor","volume":"59","author":"Flores-Mu\u00f1oz","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib91","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1124\/pr.118.017129_bib92","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/jm00085a013","article-title":"Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation","volume":"35","author":"Fourni\u00e9-Zaluski","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib93","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib94","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nm0796-814","article-title":"Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough","volume":"2","author":"Fox","year":"1996","journal-title":"Nat Med"},{"key":"10.1124\/pr.118.017129_bib95","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2119\/2007-00073.Fraga-Silva","article-title":"The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets","volume":"14","author":"Fraga-Silva","year":"2008","journal-title":"Mol Med"},{"key":"10.1124\/pr.118.017129_bib96","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib97","doi-asserted-by":"crossref","first-page":"15946","DOI":"10.1074\/jbc.M400149200","article-title":"Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice","volume":"279","author":"Fuchs","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.107.097865","article-title":"Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo","volume":"51","author":"Fuchs","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellsig.2018.06.007","article-title":"Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor","volume":"50","author":"Gaidarov","year":"2018","journal-title":"Cell Signal"},{"key":"10.1124\/pr.118.017129_bib100","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.116.08118","article-title":"Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor","volume":"68","author":"Galandrin","year":"2016","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.6879184","article-title":"Angiotensin synthesis in the brain and increased turnover in hypertensive rats","volume":"221","author":"Ganten","year":"1983","journal-title":"Science"},{"key":"10.1124\/pr.118.017129_bib102","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11010-008-9884-4","article-title":"Angiotensin metabolites can stimulate receptors of the Mas-related genes family","volume":"319","author":"Gembardt","year":"2008","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/pr.118.017129_bib103","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.RES.0000081593.33848.FC","article-title":"Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors","volume":"93","author":"Georgiadis","year":"2003","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib104","doi-asserted-by":"crossref","first-page":"1032.3","DOI":"10.1096\/fasebj.24.1_supplement.1032.3","article-title":"Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug","volume":"24","author":"Gjymishka","year":"2010","journal-title":"FASEB J"},{"key":"10.1124\/pr.118.017129_bib105","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/194867a0","article-title":"A mammalian peptidase specific for the hydrolysis of N-terminal \u03b1-L-glutamyl and aspartyl residues","volume":"194","author":"Glenner","year":"1962","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib106","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.bmcl.2011.03.109","article-title":"Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors","volume":"21","author":"Glossop","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/pr.118.017129_bib107","doi-asserted-by":"crossref","first-page":"37074","DOI":"10.1074\/jbc.M707251200","article-title":"Asparatic acid 221 is critical in the calcium-induced modulation of the enzymatic activity of human aminopeptidase A","volume":"282","author":"Goto","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib108","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib109","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/CS20070160","article-title":"ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts","volume":"113","author":"Grobe","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.118.017129_bib111","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/HYPERTENSIONAHA.110.167171","article-title":"Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling","volume":"57","author":"Guimar\u00e3es","year":"2011","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-0115(93)90438-E","article-title":"Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin","volume":"49","author":"Gyurko","year":"1993","journal-title":"Regul Pept"},{"key":"10.1124\/pr.118.017129_bib113","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.1016\/S0021-9258(17)34119-4","article-title":"Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B","volume":"269","author":"Hagiwara","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib114","doi-asserted-by":"crossref","first-page":"24108","DOI":"10.1074\/jbc.M400092200","article-title":"Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation","volume":"279","author":"Hansen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.118.017129_bib116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1023\/A:1018941626731","article-title":"Clearance mechanisms of atrial and brain natriuretic peptides in rats","volume":"11","author":"Hashimoto","year":"1994","journal-title":"Pharm Res"},{"key":"10.1124\/pr.118.017129_bib117","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ J"},{"key":"10.1124\/pr.118.017129_bib118","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.1073\/pnas.0508782102","article-title":"Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure","volume":"102","author":"Hawkridge","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib119","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(93)90997-2","article-title":"Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II","volume":"606","author":"Healy","year":"1993","journal-title":"Brain Res"},{"key":"10.1124\/pr.118.017129_bib121","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents","volume":"51","author":"Hern\u00e1ndez Prada","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj3270023","article-title":"Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin","volume":"327","author":"Hoang","year":"1997","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvs420","article-title":"Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction","volume":"97","author":"Huang","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1124\/pr.118.017129_bib124","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.RES.77.6.1070","article-title":"Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells","volume":"77","author":"Ichiki","year":"1995","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.19.6.753","article-title":"Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells","volume":"19","author":"Imai","year":"1992","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib126","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.HYP.35.6.1221","article-title":"Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats","volume":"35","author":"Intengan","year":"2000","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib127","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","article-title":"Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology","volume":"117","author":"Israili","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1124\/pr.118.017129_bib128","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0014-5793(88)80867-6","article-title":"Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin","volume":"231","author":"Itoh","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1124\/pr.118.017129_bib129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejphar.2008.02.090","article-title":"Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives","volume":"585","author":"Iusuf","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib130","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","article-title":"Metabolic regulation of brain Abeta by neprilysin","volume":"292","author":"Iwata","year":"2001","journal-title":"Science"},{"key":"10.1124\/pr.118.017129_bib131","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/01.HYP.0000017283.67962.02","article-title":"Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A","volume":"39","author":"Jackman","year":"2002","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib132","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/335437a0","article-title":"The mas oncogene encodes an angiotensin receptor","volume":"335","author":"Jackson","year":"1988","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib133","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/sj.jhh.1002018","article-title":"Dual ACE\/NEP inhibitors\u2014more than playing the ACE card","volume":"20","author":"Jandeleit-Dahm","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.118.017129_bib134","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1096\/fj.11-185470","article-title":"Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects","volume":"25","author":"Jankowski","year":"2011","journal-title":"FASEB J"},{"key":"10.1124\/pr.118.017129_bib135","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMe1900139","article-title":"PIONEERing the in-hospital initiation of sacubitril-valsartan","volume":"380","author":"Jarcho","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib136","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1124\/pr.118.017129_bib137","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.jhh.1002009","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE\/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients","volume":"20","author":"Johnson","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.118.017129_bib138","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/jm9010803","article-title":"Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors","volume":"53","author":"Jullien","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib139","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-3565(24)29576-8","article-title":"RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis","volume":"297","author":"Junot","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.118.017129_bib140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2008.647","article-title":"The kallikrein-kinin system in health and in diseases of the kidney","volume":"75","author":"Kakoki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1124\/pr.118.017129_bib141","doi-asserted-by":"crossref","first-page":"24543","DOI":"10.1016\/S0021-9258(19)74499-8","article-title":"Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition","volume":"268","author":"Kambayashi","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib142","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1432-1033.1996.0558u.x","article-title":"Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascular-smooth-muscle cells","volume":"239","author":"Kambayashi","year":"1996","journal-title":"Eur J Biochem"},{"key":"10.1124\/pr.118.017129_bib143","doi-asserted-by":"crossref","first-page":"C1389","DOI":"10.1152\/ajpcell.1994.267.5.C1389","article-title":"Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein","volume":"267","author":"Kang","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.118.017129_bib144","doi-asserted-by":"crossref","first-page":"C278","DOI":"10.1152\/ajpcell.1995.268.1.C278","article-title":"Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment","volume":"268","author":"Kang","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.118.017129_bib145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.13742","article-title":"Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22","volume":"174","author":"Karnik","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib146","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [published correction appears in Pharmacol Rev (2015) 67:820]","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib147","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.118.017129_bib148","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"1974","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib149","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CCM.0000000000002368","article-title":"The confusion assessment method for the ICU-7 delirium severity scale: a novel delirium severity instrument for use in the ICU","volume":"45","author":"Khan","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1124\/pr.118.017129_bib150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/01.HYP.27.3.529","article-title":"Regulation of angiotensin II type 2 receptor gene by the protein kinase C-calcium pathway","volume":"27","author":"Kijima","year":"1996","journal-title":"Hypertension"},{"issue":"Suppl 5","key":"10.1124\/pr.118.017129_bib151","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00005344-198900135-00003","article-title":"Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1","volume":"13","author":"Kimura","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.118.017129_bib152","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1055\/s-0038-1656996","article-title":"Plasma high molecular weight kininogen concentration in health and in chosen impairments of haemostasis. Evidence that plasmin uncovers a new antigenic site in high molecular weight kininogen","volume":"42","author":"Kleniewski","year":"1979","journal-title":"Thromb Haemost"},{"key":"10.1124\/pr.118.017129_bib153","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/eurheartj\/ehp012","article-title":"The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?","volume":"30","author":"Klotz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.118.017129_bib154","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","article-title":"Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)","volume":"2","author":"Komers","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1124\/pr.118.017129_bib155","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pr.118.017129_bib156","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.01.077","article-title":"Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction","volume":"258","author":"Kompa","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1124\/pr.118.017129_bib157","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/002215549904700403","article-title":"Cellular distribution of endothelin-converting enzyme-1 in human tissues","volume":"47","author":"Korth","year":"1999","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/pr.118.017129_bib158","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/01.CIR.0000160867.23556.7D","article-title":"G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor","volume":"111","author":"Kostenis","year":"2005","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib159","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.118.017129_bib160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE inhibitor-induced angioedema: a review","volume":"20","author":"Kostis","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/pr.118.017129_bib161","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1096\/fj.08-107300","article-title":"A protein complex in the brush-border membrane explains a Hartnup disorder allele","volume":"22","author":"Kowalczuk","year":"2008","journal-title":"FASEB J"},{"key":"10.1124\/pr.118.017129_bib162","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1021\/bi9011226","article-title":"Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme","volume":"48","author":"Kr\u00f6ger","year":"2009","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib163","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular physiology of membrane guanylyl cyclase receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol Rev"},{"issue":"Suppl 3","key":"10.1124\/pr.118.017129_bib164","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00005344-199506263-00021","article-title":"Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme","volume":"26","author":"Kukkola","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.118.017129_bib165","doi-asserted-by":"crossref","first-page":"H1069","DOI":"10.1152\/ajpheart.2000.278.4.H1069","article-title":"Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma","volume":"278","author":"Kuoppala","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/pr.118.017129_bib166","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/0006-291X(86)91040-5","article-title":"Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces","volume":"135","author":"Lachance","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.118.017129_bib167","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.biochi.2010.03.011","article-title":"Kininogens: more than cysteine protease inhibitors and kinin precursors","volume":"92","author":"Lalmanach","year":"2010","journal-title":"Biochimie"},{"key":"10.1124\/pr.118.017129_bib168","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib169","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.118.017129_bib170","first-page":"415","article-title":"Cardioprotective effects of vasopeptidase inhibitors","volume":"18","author":"Lapointe","year":"2002","journal-title":"Can J Cardiol"},{"key":"10.1124\/pr.118.017129_bib171","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system [published correction appears in Circ Res (2013) 112:e156]","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib172","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1469-7580.2009.01058.x","article-title":"The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats","volume":"214","author":"Leal","year":"2009","journal-title":"J Anat"},{"key":"10.1124\/pr.118.017129_bib173","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib174","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/14756369309040752","article-title":"Inhibition of aminopeptidases by phosphonic acid and phosphinic acid analogues of aspartic and glutamic acids","volume":"7","author":"Lejczak","year":"1993","journal-title":"J Enzyme Inhib"},{"key":"10.1124\/pr.118.017129_bib175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/frne.1997.0155","article-title":"Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review","volume":"18","author":"Lenkei","year":"1997","journal-title":"Front Neuroendocrinol"},{"key":"10.1124\/pr.118.017129_bib176","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating disease at the RNA level with oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib177","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1124\/pr.118.017129_bib178","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib179","doi-asserted-by":"crossref","first-page":"F784","DOI":"10.1152\/ajprenal.00455.2011","article-title":"Angiotensin-(1-7)-induced activation of ERK1\/2 is cAMP\/protein kinase A-dependent in glomerular mesangial cells","volume":"302","author":"Liu","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pr.118.017129_bib180","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0006-291X(80)91371-6","article-title":"Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides","volume":"96","author":"Llorens","year":"1980","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.118.017129_bib181","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00692761","article-title":"Study on aminopeptidase A","volume":"67","author":"Lojda","year":"1980","journal-title":"Histochemistry"},{"key":"10.1124\/pr.118.017129_bib182","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1007\/s00216-019-01771-9","article-title":"A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain","volume":"411","author":"Lombard-Banek","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"10.1124\/pr.118.017129_bib183","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1471-4159.2011.07552.x","article-title":"Angiotensin-(1-7) through Mas receptor up-regulates neuronal norepinephrine transporter via Akt and Erk1\/2-dependent pathways","volume":"120","author":"Lopez Verrilli","year":"2012","journal-title":"J Neurochem"},{"key":"10.1124\/pr.118.017129_bib184","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.regpep.2012.12.003","article-title":"Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-Akt signaling pathways","volume":"181","author":"Ma","year":"2013","journal-title":"Regul Pept"},{"key":"10.1124\/pr.118.017129_bib185","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib186","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib187","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","article-title":"Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy","volume":"221","author":"Malek","year":"2019","journal-title":"Life Sci"},{"key":"10.1124\/pr.118.017129_bib188","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/276523a0","article-title":"High-affinity enkephalin-degrading peptidase in brain is increased after morphine","volume":"276","author":"Malfroy","year":"1978","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib189","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib190","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib191","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/01.HYP.33.3.835","article-title":"Enhancement of bradykinin and resensitization of its B2 receptor","volume":"33","author":"Marcic","year":"1999","journal-title":"Hypertension"},{"issue":"3","key":"10.1124\/pr.118.017129_bib396","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/febs.12660","article-title":"Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme","volume":"281","author":"Masuyer","year":"2014","journal-title":"FEBS J"},{"key":"10.1124\/pr.118.017129_bib192","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/srep00717","article-title":"Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides","volume":"2","author":"Masuyer","year":"2012","journal-title":"Sci Rep"},{"key":"10.1124\/pr.118.017129_bib193","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ki.2013.453","article-title":"Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation","volume":"85","author":"Matsusaka","year":"2014","journal-title":"Kidney Int"},{"key":"10.1124\/pr.118.017129_bib194","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2011121159","article-title":"Liver angiotensinogen is the primary source of renal angiotensin II","volume":"23","author":"Matsusaka","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pr.118.017129_bib195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/pr.118.017129_bib196","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib197","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/HYPERTENSIONAHA.118.12012","article-title":"Design, synthesis, and actions of an innovative bispecific designer peptide","volume":"73","author":"Meems","year":"2019","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib198","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacbts.2016.10.001","article-title":"Innovative therapeutics: designer natriuretic peptides","volume":"1","author":"Meems","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1124\/pr.118.017129_bib199","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ijcard.2012.10.007","article-title":"The past, present and future of renin-angiotensin aldosterone system inhibition","volume":"167","author":"Mentz","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1124\/pr.118.017129_bib200","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0196-9781(96)00036-8","article-title":"The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A","volume":"17","author":"Migaud","year":"1996","journal-title":"Peptides"},{"key":"10.1124\/pr.118.017129_bib201","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1073\/pnas.88.24.11440","article-title":"Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development","volume":"88","author":"Millan","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib202","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.1139","article-title":"Effect of sacubitril\/valsartan on recurrent events in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/pr.118.017129_bib203","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.102.038067","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin","volume":"303","author":"Molinaro","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.118.017129_bib204","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCHEARTFAILURE.113.000672","article-title":"Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db\/db mice by reducing lipotoxicity and inflammation","volume":"7","author":"Mori","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1124\/pr.118.017129_bib205","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","author":"Morrow","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.118.017129_bib206","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pharmthera.2005.08.012","article-title":"Endothelin receptor antagonists","volume":"110","author":"Motte","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.118.017129_bib207","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11897-008-0030-0","article-title":"Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials","volume":"5","author":"Moukarbel","year":"2008","journal-title":"Curr Heart Fail Rep"},{"key":"10.1124\/pr.118.017129_bib208","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI115146","article-title":"Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide","volume":"87","author":"Mukoyama","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.118.017129_bib209","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/351233a0","article-title":"Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor","volume":"351","author":"Murphy","year":"1991","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib211","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2\u2032-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib212","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1021\/jm020138n","article-title":"Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists","volume":"45","author":"Murugesan","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib213","first-page":"F62","article-title":"Inhibition of renin release from rat kidney slices by the angiotensins","volume":"235","author":"Naftilan","year":"1978","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.118.017129_bib214","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0005-2744(70)90058-6","article-title":"Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme","volume":"198","author":"Nagatsu","year":"1970","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pr.118.017129_bib215","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12178","article-title":"Monitoring G protein-coupled receptor and \u03b2-arrestin trafficking in live cells using enhanced bystander BRET","volume":"7","author":"Namkung","year":"2016","journal-title":"Nat Commun"},{"key":"10.1124\/pr.118.017129_bib216","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11906-013-0416-6","article-title":"AT(2) receptor and tissue injury: therapeutic implications","volume":"16","author":"Namsolleck","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/pr.118.017129_bib217","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature01370","article-title":"Crystal structure of the human angiotensin-converting enzyme-lisinopril complex","volume":"421","author":"Natesh","year":"2003","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib218","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00132580-200111000-00006","article-title":"Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase","volume":"3","author":"Nawarskas","year":"2001","journal-title":"Heart Dis"},{"key":"10.1124\/pr.118.017129_bib219","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1016\/j.bmcl.2006.06.004","article-title":"Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme","volume":"16","author":"Nchinda","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/pr.118.017129_bib220","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1016\/j.bmcl.2006.06.003","article-title":"Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors","volume":"16","author":"Nchinda","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"Suppl 18","key":"10.1124\/pr.118.017129_bib221","first-page":"S886","article-title":"Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension (Abstract)","volume":"118","author":"Neutel","year":"2008","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib222","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/HJH.0b013e328335d291","article-title":"Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro","volume":"28","author":"Ocaranza","year":"2010","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib223","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","article-title":"Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme\/Ang II axis","volume":"32","author":"Ocaranza","year":"2014","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib224","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure [published correction appears in N Engl J Med (2011) 365:773]","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1124\/pr.118.017129_bib226","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1107\/S0907444907036281","article-title":"Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV","volume":"63","author":"Oefner","year":"2007","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/pr.118.017129_bib227","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1107\/S0907444903027410","article-title":"Structural analysis of neprilysin with various specific and potent inhibitors","volume":"60","author":"Oefner","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/pr.118.017129_bib228","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYPERTENSIONAHA.113.02426","article-title":"Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade","volume":"63","author":"Ohshima","year":"2014","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib229","first-page":"F546","article-title":"Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor","volume":"263","author":"Okolicany","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.118.017129_bib230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.118.017129_bib231","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1515\/BC.2008.131","article-title":"The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme","volume":"389","author":"O\u2019Neill","year":"2008","journal-title":"Biol Chem"},{"key":"10.1124\/pr.118.017129_bib232","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/pr.118.017129_bib233","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib234","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3122\/jabfm.2017.04.170111","article-title":"Angioedema spotlight: a closer examination of sacubitril\/valsartan safety results","volume":"30","author":"Owens","year":"2017","journal-title":"J Am Board Fam Med"},{"key":"10.1124\/pr.118.017129_bib235","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib236","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pr.118.017129_bib237","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1124\/pr.118.017129_bib238","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.71.1.29","article-title":"A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator","volume":"71","author":"Page","year":"1940","journal-title":"J Exp Med"},{"key":"10.1124\/pr.118.017129_bib239","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.peptides.2004.09.024","article-title":"Biology of natriuretic peptides and their receptors","volume":"26","author":"Pandey","year":"2005","journal-title":"Peptides"},{"key":"10.1124\/pr.118.017129_bib240","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.phrs.2016.02.026","article-title":"Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db\/db) by reducing oxidative stress, inflammation and pathological remodeling","volume":"107","author":"Papinska","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1124\/pr.118.017129_bib241","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib242","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.ph.49.030187.002213","article-title":"Functions of angiotensin in the central nervous system","volume":"49","author":"Phillips","year":"1987","journal-title":"Annu Rev Physiol"},{"key":"10.1124\/pr.118.017129_bib243","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.0000141438.64887.42","article-title":"Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney","volume":"44","author":"Pinheiro","year":"2004","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib244","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1124\/pr.118.017129_bib245","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib246","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1124\/pr.118.017129_bib247","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J"},{"key":"10.1124\/pr.118.017129_bib248","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00004872-200205000-00025","article-title":"Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE\/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats","volume":"20","author":"Pu","year":"2002","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib249","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1210\/endo-128-4-1947","article-title":"Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor","volume":"128","author":"Pucell","year":"1991","journal-title":"Endocrinology"},{"key":"10.1124\/pr.118.017129_bib250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.regpep.2010.02.007","article-title":"Distribution of a novel binding site for angiotensins II and III in mouse tissues","volume":"162","author":"Rabey","year":"2010","journal-title":"Regul Pept"},{"key":"10.1124\/pr.118.017129_bib251","first-page":"169","article-title":"Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements","volume":"1","author":"Rabin","year":"1987","journal-title":"Oncogene Res"},{"key":"10.1124\/pr.118.017129_bib252","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM198608283150901","article-title":"Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure","volume":"315","author":"Raine","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib253","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pr.118.017129_bib254","doi-asserted-by":"crossref","first-page":"F349","DOI":"10.1152\/ajprenal.00478.2014","article-title":"Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2","volume":"308","author":"Ravichandran","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pr.118.017129_bib255","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib256","doi-asserted-by":"crossref","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib257","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06836-X","article-title":"Pharmacology of bradykinin and related kinins","volume":"32","author":"Regoli","year":"1980","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib258","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.117.312422","article-title":"(Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis","volume":"122","author":"Ren","year":"2018","journal-title":"Circ Res"},{"key":"10.1124\/pr.118.017129_bib259","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/01.HYP.0000244543.91937.79","article-title":"Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study","volume":"48","author":"Rice","year":"2006","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib261","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0960-894X(01)80371-1","article-title":"Mercaptoacyl dipeptides as dual inhibitors of angiotensin converting enzyme and neutral peptidase. Preliminary structure-activity studies","volume":"4","author":"Robl","year":"1994","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/pr.118.017129_bib262","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm980542f","article-title":"Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides","volume":"42","author":"Robl","year":"1999","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib263","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/jm970041e","article-title":"Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase","volume":"40","author":"Robl","year":"1997","journal-title":"J Med Chem"},{"key":"10.1124\/pr.118.017129_bib264","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/wound.2014.0609","article-title":"NorLeu3-angiotensin (1-7) [DSC127] as a therapy for the healing of diabetic foot ulcers","volume":"4","author":"Rodgers","year":"2015","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1124\/pr.118.017129_bib265","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/HYPERTENSIONAHA.115.07012","article-title":"On the origin of urinary renin: a translational approach","volume":"67","author":"Roksnoer","year":"2016","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib266","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int"},{"key":"10.1124\/pr.118.017129_bib267","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib268","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/288286a0","article-title":"The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice","volume":"288","author":"Roques","year":"1980","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib269","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","article-title":"Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology","volume":"45","author":"Roques","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib270","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2015.02.038","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"65","author":"Rosendorff","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib271","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1373\/clinchem.2015.239673","article-title":"Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study","volume":"61","author":"R\u00f8sj\u00f8","year":"2015","journal-title":"Clin Chem"},{"key":"10.1124\/pr.118.017129_bib272","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0008-6363(99)00110-8","article-title":"Interactions between endothelin-1 and the renin-angiotensin-aldosterone system","volume":"43","author":"Rossi","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1124\/pr.118.017129_bib273","doi-asserted-by":"crossref","first-page":"29242","DOI":"10.1074\/jbc.M204406200","article-title":"Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A","volume":"277","author":"Rozenfeld","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib274","doi-asserted-by":"crossref","first-page":"14785","DOI":"10.1021\/bi034358u","article-title":"Contribution of molecular modeling and site-directed mutagenesis to the identification of a new residue, glutamate 215, involved in the exopeptidase specificity of aminopeptidase A","volume":"42","author":"Rozenfeld","year":"2003","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib275","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0031-6997(25)06809-7","article-title":"Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology","volume":"46","author":"Rubanyi","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.118.017129_bib276","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1097\/HJH.0000000000001762","article-title":"Effects of dual angiotensin type 1 receptor\/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat","volume":"36","author":"Rubattu","year":"2018","journal-title":"J Hypertens"},{"key":"10.1124\/pr.118.017129_bib277","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib278","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0702315","article-title":"Secretory pathways in endothelin synthesis","volume":"126","author":"Russell","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib279","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/hlca.200590051","article-title":"Second-generation inhibitors for the metalloprotease neprilysin based on bicyclic heteroaromatic scaffolds: synthesis, biological activity, and X-ray crystal-structure analysis","volume":"88","author":"Sahli","year":"2005","journal-title":"Helv Chim Acta"},{"key":"10.1124\/pr.118.017129_bib280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11906-005-0088-y","article-title":"Molecular evidence of tissue renin-angiotensin systems: a focus on the brain","volume":"7","author":"Sakai","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/pr.118.017129_bib281","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.HYP.0000251865.35728.2f","article-title":"Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways","volume":"49","author":"Sampaio","year":"2007","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib282","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1016\/S0021-9258(19)50109-0","article-title":"Cloning and expression of a novel angiotensin II receptor subtype","volume":"267","author":"Sandberg","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib283","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0361-9230(94)90104-X","article-title":"Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors","volume":"35","author":"Santos","year":"1994","journal-title":"Brain Res Bull"},{"key":"10.1124\/pr.118.017129_bib284","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1124\/pr.118.017129_bib285","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib286","doi-asserted-by":"crossref","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","article-title":"The renin-angiotensin system: going beyond the classical paradigms","volume":"316","author":"Santos","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/pr.118.017129_bib287","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1124\/pr.118.017129_bib288","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/351230a0","article-title":"Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor","volume":"351","author":"Sasaki","year":"1991","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib289","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1124\/pr.118.017129_bib290","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4592768","article-title":"Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma","volume":"2016","author":"Savage","year":"2016","journal-title":"Sarcoma"},{"key":"10.1124\/pr.118.017129_bib291","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/HYPERTENSIONAHA.110.152942","article-title":"Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor","volume":"56","author":"Savergnini","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib292","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057757","article-title":"The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats","volume":"8","author":"Savergnini","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/pr.118.017129_bib397","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of active proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.118.017129_bib293","doi-asserted-by":"crossref","DOI":"10.1038\/srep27909","article-title":"Structure of neprilysin in complex with the active metabolite of sacubitril","volume":"6","author":"Schiering","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/pr.118.017129_bib294","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jmb.2008.10.052","article-title":"Structure of human endothelin-converting enzyme I complexed with phosphoramidon","volume":"385","author":"Schulz","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1124\/pr.118.017129_bib295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.CIR.95.1.39","article-title":"Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women","volume":"95","author":"Schunkert","year":"1997","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib296","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuint.2011.11.008","article-title":"AT2 receptors recruit c-Src, SHP-1 and FAK upon activation by Ang II in PND15 rat hindbrain","volume":"60","author":"Seguin","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1124\/pr.118.017129_bib297","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199103000-00015","article-title":"Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme","volume":"17","author":"Seymour","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.118.017129_bib298","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/1470320314568438","article-title":"Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats","volume":"16","author":"Sharp","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1124\/pr.118.017129_bib299","doi-asserted-by":"crossref","first-page":"34643","DOI":"10.1074\/jbc.M805181200","article-title":"Discovery and validation of novel peptide agonists for G-protein-coupled receptors","volume":"283","author":"Shemesh","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib300","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/HYPERTENSIONAHA.114.03871","article-title":"Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension","volume":"64","author":"Shenoy","year":"2014","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib301","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/jcbfm.2015.30","article-title":"Angiotensin-(1-7) protects against the development of aneurysmal subarachnoid hemorrhage in mice","volume":"35","author":"Shimada","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1124\/pr.118.017129_bib302","doi-asserted-by":"crossref","first-page":"21895","DOI":"10.1074\/jbc.M008511200","article-title":"Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases","volume":"276","author":"Shirotani","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib303","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/HYPERTENSIONAHA.117.09167","article-title":"No brain renin-angiotensin system: d\u00e9j\u00e0 vu all over again?","volume":"69","author":"Sigmund","year":"2017","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib304","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1001\/archinte.1992.00400200128023","article-title":"Cough and ACE inhibitors","volume":"152","author":"Simon","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1124\/pr.118.017129_bib305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.103.3.295","article-title":"The preparation and function of the hypertensin-converting enzyme","volume":"103","author":"Skeggs","year":"1956","journal-title":"J Exp Med"},{"key":"10.1124\/pr.118.017129_bib306","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"10.1124\/pr.118.017129_bib307","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1124\/pr.118.017129_bib308","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib309","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cne.903160407","article-title":"Mapping of angiotensin II receptor subtype heterogeneity in rat brain","volume":"316","author":"Song","year":"1992","journal-title":"J Comp Neurol"},{"key":"10.1124\/pr.118.017129_bib310","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00005344-199705000-00007","article-title":"Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue","volume":"29","author":"Soualmia","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.118.017129_bib311","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1073\/pnas.85.24.9386","article-title":"Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning","volume":"85","author":"Soubrier","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib312","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1124\/pr.118.017129_bib313","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0024-3205(89)90200-2","article-title":"Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo","volume":"45","author":"Stasch","year":"1989","journal-title":"Life Sci"},{"key":"10.1124\/pr.118.017129_bib314","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/000155501317140007","article-title":"Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions","volume":"81","author":"Steckelings","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1124\/pr.118.017129_bib315","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.tem.2017.06.002","article-title":"Centrally mediated cardiovascular actions of the angiotensin II type 2 receptor","volume":"28","author":"Steckelings","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"10.1124\/pr.118.017129_bib316","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1124\/pr.118.017129_bib317","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1460-9568.2005.04188.x","article-title":"In vivo characterization of the angiotensin-(1-7)-induced dopamine and \u03b3-aminobutyric acid release in the striatum of the rat","volume":"22","author":"Stragier","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1124\/pr.118.017129_bib318","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaci.2016.09.051","article-title":"Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema","volume":"140","author":"Straka","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1124\/pr.118.017129_bib395","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1042\/BCJ20190290","article-title":"Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb)","volume":"476","author":"Sturrock","year":"2019","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib319","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1124\/jpet.105.084749","article-title":"Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11\/angiotensin-converting enzyme inhibitor GW796406","volume":"315","author":"Sulpizio","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.118.017129_bib320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circj.69.283","article-title":"Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the \u2018real world\u2019 of therapy","volume":"69","author":"Suwa","year":"2005","journal-title":"Circ J"},{"key":"10.1124\/pr.118.017129_bib321","first-page":"1414","article-title":"Omapatrilat. Bristol-Myers Squibb","volume":"2","author":"Tabrizchi","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pr.118.017129_bib322","doi-asserted-by":"crossref","first-page":"21394","DOI":"10.1016\/S0021-9258(19)36936-4","article-title":"Purification and characterization of endothelin-converting enzyme from rat lung","volume":"268","author":"Takahashi","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib323","doi-asserted-by":"crossref","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","article-title":"Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/pr.118.017129_bib324","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/0929867321666141106113018","article-title":"New antihypertensive drugs under development","volume":"22","author":"Tamargo","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1124\/pr.118.017129_bib325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib326","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1074\/jbc.M113.459792","article-title":"Control of adipogenesis by the autocrine interplays between angiotensin 1-7\/Mas receptor and angiotensin II\/AT1 receptor signaling pathways","volume":"288","author":"Than","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib327","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0306-4522(88)90029-2","article-title":"Immunocytochemical localization of angiotensinogen in the rat brain","volume":"25","author":"Thomas","year":"1988","journal-title":"Neuroscience"},{"key":"10.1124\/pr.118.017129_bib328","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/84117","article-title":"Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation","volume":"8","author":"Thunnissen","year":"2001","journal-title":"Nat Struct Biol"},{"key":"10.1124\/pr.118.017129_bib329","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103520","article-title":"Atypical signaling and functional desensitization response of MAS receptor to peptide ligands","volume":"9","author":"Tirupula","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pr.118.017129_bib331","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.HYP.38.1.95","article-title":"Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade","volume":"38","author":"Tom","year":"2001","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib332","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","article-title":"Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits","volume":"72","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib333","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.beem.2018.02.003","article-title":"Novel mechanisms of G-protein-coupled receptors functions: AT1 angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk","volume":"32","author":"T\u00f3th","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1124\/pr.118.017129_bib334","doi-asserted-by":"crossref","first-page":"17996","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","volume":"279","author":"Towler","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib335","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1527-3466.2007.00012.x","article-title":"Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments","volume":"25","author":"Trask","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/pr.118.017129_bib336","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0895-7061(97)00404-4","article-title":"Effects of omapatrilat in low, normal, and high renin experimental hypertension","volume":"11","author":"Trippodo","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.118.017129_bib337","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/0960-894X(95)00316-L","article-title":"Diastereoselective synthesis of mixanpril, an orally active dual inhibitor of neutral endopeptidase and angiotensin converting enzyme","volume":"5","author":"Turcaud","year":"1995","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/pr.118.017129_bib338","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1096\/fasebj.11.5.9141502","article-title":"Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX","volume":"11","author":"Turner","year":"1997","journal-title":"FASEB J"},{"key":"10.1124\/pr.118.017129_bib339","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1042\/CS20180236","article-title":"Angiotensin generation in the brain: a re-evaluation","volume":"132","author":"Uijl","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.118.017129_bib341","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.HYP.0000151323.93372.f5","article-title":"Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction","volume":"45","author":"van Esch","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib342","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.116.08922","article-title":"Brain renin\u2013angiotensin system: does it exist?","volume":"69","author":"van Thiel","year":"2017","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib343","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MNH.0000000000000050","article-title":"Angiotensin-(1-7) as a strategy in the treatment of hypertension?","volume":"23","author":"van Twist","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/pr.118.017129_bib344","first-page":"2673","article-title":"Activation of the mas oncogene involves coupling to human alphoid sequences","volume":"8","author":"van\u2019t Veer","year":"1993","journal-title":"Oncogene"},{"key":"10.1124\/pr.118.017129_bib345","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1124\/pr.118.017129_bib346","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1042\/bj3270883","article-title":"A tyrosine residue essential for catalytic activity in aminopeptidase A","volume":"327","author":"Vazeux","year":"1997","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib347","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/bj3340407","article-title":"A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A","volume":"334","author":"Vazeux","year":"1998","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib348","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1074\/jbc.271.15.9069","article-title":"Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A","volume":"271","author":"Vazeux","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib349","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.bjp.0705262","article-title":"Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives","volume":"139","author":"Veerasingham","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.118.017129_bib350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib351","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/HYPERTENSIONAHA.115.05267","article-title":"Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression","volume":"65","author":"Verdonk","year":"2015","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib352","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib353","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1016\/S0021-9258(18)77280-3","article-title":"The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)","volume":"265","author":"Vijayaraghavan","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib354","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cardiores.2007.02.032","article-title":"Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor","volume":"74","author":"Villar","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1124\/pr.118.017129_bib355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1124\/pr.118.017129_bib356","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","article-title":"Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats","volume":"45","author":"Walters","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib357","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1073\/pnas.90.4.1222","article-title":"Histidine residue in the zinc-binding motif of aminopeptidase A is critical for enzymatic activity","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib358","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1021\/bi8002605","article-title":"Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme","volume":"47","author":"Watermeyer","year":"2008","journal-title":"Biochemistry"},{"key":"10.1124\/pr.118.017129_bib359","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/BJ20100056","article-title":"Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril","volume":"428","author":"Watermeyer","year":"2010","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib360","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"10.1124\/pr.118.017129_bib361","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(01)06584-9","article-title":"Vasopeptidase inhibitors","volume":"358","author":"Weber","year":"2001","journal-title":"Lancet"},{"key":"10.1124\/pr.118.017129_bib362","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/HYPERTENSIONAHA.108.111393","article-title":"Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk","volume":"51","author":"Weber","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib363","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/pr.118.017129_bib364","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.88.3.1004","article-title":"Natriuretic peptide system in human heart failure","volume":"88","author":"Wei","year":"1993","journal-title":"Circulation"},{"key":"10.1124\/pr.118.017129_bib365","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1016\/S0021-9258(18)42224-7","article-title":"The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors","volume":"267","author":"Wei","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib366","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0024-3205(93)90108-F","article-title":"A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11","volume":"52","author":"Welches","year":"1993","journal-title":"Life Sci"},{"key":"10.1124\/pr.118.017129_bib367","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib368","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.HYP.25.3.314","article-title":"Antisense inhibition of hypertension in the spontaneously hypertensive rat","volume":"25","author":"Wielbo","year":"1995","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib369","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.HYP.0000037979.53963.8F","article-title":"AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium","volume":"40","author":"Wiemer","year":"2002","journal-title":"Hypertension"},{"key":"10.1124\/pr.118.017129_bib370","doi-asserted-by":"crossref","first-page":"29430","DOI":"10.1016\/S0021-9258(18)43897-5","article-title":"Identification of two active site residues in human angiotensin I-converting enzyme","volume":"269","author":"Williams","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib371","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1042\/bj3470711","article-title":"Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites","volume":"347","author":"Woodman","year":"2000","journal-title":"Biochem J"},{"key":"10.1124\/pr.118.017129_bib372","article-title":"First-line drugs for hypertension","volume":"4","author":"Wright","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pr.118.017129_bib373","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0167-0115(95)00084-O","article-title":"Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions","volume":"59","author":"Wright","year":"1995","journal-title":"Regul Pept"},{"key":"10.1124\/pr.118.017129_bib374","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0165-0173(97)00019-2","article-title":"Important role for angiotensin III and IV in the brain renin-angiotensin system","volume":"25","author":"Wright","year":"1997","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1124\/pr.118.017129_bib375","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0361-9230(93)90297-O","article-title":"Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory","volume":"32","author":"Wright","year":"1993","journal-title":"Brain Res Bull"},{"key":"10.1124\/pr.118.017129_bib376","doi-asserted-by":"crossref","first-page":"R725","DOI":"10.1152\/ajpregu.00326.2002","article-title":"Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats","volume":"284","author":"Wright","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pr.118.017129_bib377","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0092-8674(94)90425-1","article-title":"ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1","volume":"78","author":"Xu","year":"1994","journal-title":"Cell"},{"key":"10.1124\/pr.118.017129_bib378","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1073\/pnas.93.1.156","article-title":"Angiotensin II type 2 receptor mediates programmed cell death","volume":"93","author":"Yamada","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib379","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1073\/pnas.85.18.6964","article-title":"Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide","volume":"85","author":"Yanagisawa","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib380","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib381","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pr.118.017129_bib382","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1753944718784536","article-title":"Sacubitril\/valsartan in cardiovascular disease: evidence to date and place in therapy","volume":"12","author":"Yandrapalli","year":"2018","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1124\/pr.118.017129_bib383","doi-asserted-by":"crossref","first-page":"25638","DOI":"10.1074\/jbc.M113.494955","article-title":"Structural insights into central hypertension regulation by human aminopeptidase A","volume":"288","author":"Yang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.118.017129_bib384","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/ATVBAHA.118.311817","article-title":"Angiotensinogen and megalin interactions contribute to atherosclerosis\u2014brief report","volume":"39","author":"Ye","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.118.017129_bib385","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0092-8674(86)90785-3","article-title":"Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains","volume":"45","author":"Young","year":"1986","journal-title":"Cell"},{"key":"10.1124\/pr.118.017129_bib386","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.peptides.2016.09.009","article-title":"Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor","volume":"86","author":"Yu","year":"2016","journal-title":"Peptides"},{"key":"10.1124\/pr.118.017129_bib387","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1470320310379065","article-title":"Developmental changes in AT1 and AT2 receptor-protein expression in rats","volume":"11","author":"Yu","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1124\/pr.118.017129_bib388","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.118.017129_bib389","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11906-003-0045-6","article-title":"Recent clinical trials with omapatrilat: new developments","volume":"5","author":"Zanchi","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/pr.118.017129_bib390","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature22035","article-title":"Structural basis for selectivity and diversity in angiotensin II receptors","volume":"544","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1124\/pr.118.017129_bib391","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"2015","journal-title":"Cell"},{"key":"10.1124\/pr.118.017129_bib392","doi-asserted-by":"crossref","first-page":"H299","DOI":"10.1152\/ajpheart.00723.2011","article-title":"Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection","volume":"302","author":"Zhang","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/pr.118.017129_bib393","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pr.118.017129_bib394","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0306-4522(96)00660-4","article-title":"Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats","volume":"78","author":"Zini","year":"1997","journal-title":"Neuroscience"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724013024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724013024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.118.017129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:02:02Z","timestamp":1740765722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724013024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":398,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0031699724013024"],"URL":"https:\/\/doi.org\/10.1124\/pr.118.017129","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.118.017129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The Author(s)","name":"copyright","label":"Copyright"}]}}